Latest Content

EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.

Experts at ADA 2026 say nutrition guidelines must be personalized, culturally responsive, and built on research that reflects the patients they're meant to serve.

Robert Andrews, CEO, Healthcare Transformation Alliance, provides insight on what workers' compensation tells us about managing health care costs.

David Brueggeman, MBA, breaks down the underpriced financial risks, redetermination lessons, and what accountable AI actually requires from health plans.

A meta-analysis evaluated the efficacy of various monoclonal antibodies in treating patients with myasthenia gravis (MG).

Spanish dermatology consensus guides alopecia areata treatment escalation, highlighting JAK inhibitors, SALT-based staging, special-population care, and essential screening requirements.

Posttransplant revumenib maintenance shows promising survival and low relapse in high-risk AML subtypes, with manageable thrombocytopenia; the randomized MenTain trial is underway.

The FDA approved the first oral carbapenem, tebipenem pivoxil, for complicated UTIs, offering an alternative to intravenous therapy.

Mobile health models that include artificial intelligence and smartphone imaging can help address gaps in early detection.